B7-H6在恶性肿瘤中的研究进展

doi:10.11904/j.issn.1002-3070.2021.01.009

摘要/Abstract

摘要： B7-H6是新近发现的免疫球蛋白超家族成员,是NK细胞表面活化性受体NKP30的膜结合配体。B7-H6较特异地表达于多种肿瘤组织,并且其表达水平与多种临床病理参数及预后显著相关。细胞表面B7-H6胞外域脱落后形成可溶性B7-H6,下调NKP30介导的NK细胞毒性及细胞因子的分泌。研究发现B7-H6通过蛋白酶抑制剂、Myc、异常的免疫应答、增殖和抗凋亡等调控机制促进恶性肿瘤的发生发展。目前对B7-H6基因的干预治疗是一种新型的肿瘤治疗策略,相关的免疫治疗正在探索中。总之,B7-H6已被证明是一种潜在的生物标志物和有价值的治疗靶点,可用于癌症的诊断、治疗和预后评估。

关键词: B7-H6, sB7-H6, NKP30, 肿瘤免疫, 免疫治疗

Abstract: B7-H6,a newly discovered member of the immunoglobulin superfamily,is the membrane-binding ligand of NKP30,which is an activated receptor of the NK cell surface.B7-H6 is specifically expressed in various tumor tissues,and its expression is significantly correlated with various clinicopathological parameters and prognosis.The tumor cell ectodomain shedding of B7-H6 forms soluble B7-H6(sB7-H6),which down-regulates NKp30-mediated NK cell cytotoxicity and cytokine secretion.Studies have found that B7-H6 promotes tumorigenesis via protease inhibitors,Myc,abnormal immune response,proliferation,and anti-apoptosis.At present,the intervention therapy of the B7-H6 gene is a new tumor treatment strategy,and related immunotherapy is being explored.In summary,B7-H6 has been proved to be a potential biomarker and valuable therapeutic target for the diagnosis,treatment,prognostic evaluation of cancer.

Key words: B7-H6, sB7-H6, NKP30, Tumor immunity, Immunotherapy

中图分类号:

刘学静(综述),徐燕颖(审校). B7-H6在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 46-49.

LIU Xuejing,XU Yanying. Research progress of B7-H6 in malignant tumors[J]. Journal of Practical Oncology, 2021, 35(1): 46-49.

参考文献

1 王仪麟,林勇.B7分子家族在肿瘤免疫治疗中的应用[J].实用肿瘤学杂志,2007,21(4):387-389.
2 Chen Z,Yang Y,Liu LL,et al.Strategies to augment natural killer(NK)cell activity against solid tumors[J].Cancers,2019,11(7):1040.
3 Brandt CS,Baratin M,Yi EC,et al.The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans[J].J Exp Med,2009,206(7):1495-1503.
4 Hu Y,Zeng T,Xiao Z,et al.Immunological role and underlying mechanisms of B7-H6 in tumorigenesis[J].Clin Chim Acta,2020,502:191-198.
5 Joyce MG,Tran P,Zhuravleva MA,et al.Crystal structure of human natural cytotoxicity receptor NKp30 and identification of its ligand binding site[J].Proc Natl Acad Sci U S A,2011,108(15):6223-6228.
6 Chen L,Feng J,Xu B,et al.B7-H6 expression in human hepatocellular carcinoma and its clinical significance[J].Cancer Cell Int,2018,18:126.
7 Gutierrez-Silerio GY,Franco-Topete RA,Haramati J,et al.Positive staining of the immunoligand B7-H6 in abnormal/transformed keratinocytes consistently accompanies the progression of cervical cancer[J].BMC Immunol,2020,21(1):9.
8 Che F,Xie X,Wang L,et al.B7-H6 expression is induced by lipopolysaccharide and facilitates cancer invasion and metastasis in human gliomas[J].Int Immunopharmacol,2018,59:318-327.
9 Wang J,Jin X,Liu J,et al.The prognostic value of B7-H6 protein expression in human oral squamous cell carcinoma[J].J Oral Pathol Med,2017,46(9):766-772.
10 Zhou H,Dong J,Guo L,et al.The prognostic value of B7-H6 in esophageal squamous cell carcinoma[J].Sci Rep,2019,9(1):18122.
11 吴大广,徐兰,王振欣,等.B7-H6 mRNA在结肠癌中的表达和临床意义[J].免疫学杂志,2019,35(10):891-895.
12 Li D,Xiang S,Shen J,et al.Comprehensive understanding of B7 family in gastric cancer:expression profile,association with clinicopathological parameters and downstream targets[J].Int J Biol Sci,2020,16(4):568-582.
13 Schlecker E,Fiegler N,Arnold A,et al.Metalloprotease-mediated tumor cell shedding of B7-H6,the ligand of the natural killer cell-activating receptor NKp30[J].Cancer Res,2014,74(13):3429-3440.
14 Rusakiewicz S,Perier A,Semeraro M,et al.NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients[J].Oncoimmunology,2017,6(1):e1137418.
15 Fiegler N,Textor S,Arnold A,et al.Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells[J].Blood,2013,122(5):684-693.
16 Textor S,Bossler F,Henrich KO,et al.The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells[J].Oncoimmunology,2016,5(7):e1116674.
17 Pesce S,Tabellini G,Cantoni C,et al.B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape[J].Oncoimmunology,2015,4(4):e1001224.
18 Mantovani S,Oliviero B,Lombardi A,et al.Deficient natural killer cell NKp30-mediated function and altered NCR3 splice variants in hepatocellular carcinoma[J].Hepatology,2019,69(3):1165-1179.
19 Trabanelli S,Chevalier MF,Martinez-Usatorre A,et al.Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis[J].Nat Commun,2017,8(1):593.
20 Fasbender F,Obholzer M,Metzler S,et al.Enhanced activation of human NK cells by drug-exposed hepatocytes[J].Arch Toxicol,2020,94(2):439-448.
21 Obiedat A,Charpak-Amikam Y,Tai-Schmiedel J,et al.The integrated stress response promotes B7H6 expression[J].J Mol Med(Berl),2020,98(1):135-148.
22 Zhang B,Sun J,Yao X,et al.Knockdown of B7H6 inhibits tumor progression in triple-negative breast cancer[J].Oncol Lett,2018,16(1):91-96.
23 Li YM,Liu ZY,Li ZC,et al.Alterations of the immunologic co-stimulator B7 and TNFR families correlate with hepatocellular carcinoma prognosis and metastasis by inactivating STAT3[J].Int J Mol Sci,2019,20(1):156.
24 Xia E,Shen Y,Bhandari A,et al.Long non-coding RNA LINC00673 promotes breast cancer proliferation and metastasis through regulating B7-H6 and epithelial-mesenchymal transition[J].Am J Cancer Res,2018,8(7):1273-1287.
25 姚洋,张艳桥.胃癌免疫检查点抑制剂作用机制及最新研究进展[J].实用肿瘤学杂志,2019,33(4):371-375.
26 Gacerez AT,Hua CK,Ackerman ME,et al.Chimeric antigen receptors with human scFvs preferentially induce T cell anti-tumor activity against tumors with high B7H6 expression[J].Cancer Immunol Immunother,2018,67(5):749-759.
27 Gacerez AT,Sentman CL.T-bet promotes potent antitumor activity of CD4 CAR T cells[J].Cancer Gene Ther,2018,25(5/6):117-128.
28 Xu X,Narni-Mancinelli E,Cantoni C,et al.Structural insights into the inhibitory mechanism of an antibody against B7-H6,a stress-induced cellular ligand for the natural killer cell receptor NKp30[J].J Mol Biol,2016,428(22):4457-4466.
29 Di Lorenzo B,Simes AE,Caiado F,et al.Broad cytotoxic targeting of acute myeloid leukemia by polyclonal delta one T cells[J].Cancer Immunol Res,2019,7(4):552-558.

[1]	李瑞阳,方琳(综述),张艳桥(审校). 食管癌免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 41-45.
[2]	张璐,陆静钰(综述),陆海军(审校). 头颈部鳞癌相关生物标志物与免疫治疗预后的关系[J]. 实用肿瘤学杂志, 2021, 35(1): 55-58.
[3]	范晓娜, 王丹, 黎清炜, 李志伟. 胰腺癌术后辅助药物治疗的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 249-253.
[4]	侯建英, 朱巍. 免疫抑制剂PD-1/PD-L1治疗卵巢癌的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 266-270.
[5]	刘超, 郑桐森. 新冠肺炎时期肿瘤内科工作的总结和反思[J]. 实用肿瘤学杂志, 2020, 34(2): 100-102.
[6]	曹涤非, 黄国庆, 薛佳莹, 吴琼, 王雷, 李瑶. CA153在乳腺癌免疫治疗中的作用[J]. 实用肿瘤学杂志, 2019, 33(6): 566-569.
[7]	姚洋张艳桥. 胃癌免疫检查点抑制剂作用机制及最新研究进展[J]. 实用肿瘤学杂志, 2019, 33(4): 371-375.
[8]	孙祖刚, 王哲, 陈怀安, 刘硕, 苗文隆. 诱发膀胱癌的常见慢性炎症因素及其免疫治疗的研究进展[J]. 实用肿瘤学杂志, 2018, 32(4): 357-361.
[9]	张婷, 贾迪(综述), 杨丹(审校). 骨肉瘤的生物学治疗进展[J]. 实用肿瘤学杂志, 2018, 32(3): 254-257.
[10]	苗素平, 郭二亮, 裴荣, 姜寰宇, 苗素生. miRNA调节免疫检查点在肿瘤治疗中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 57-62.
[11]	曾玉兰,刘洋洋,梁金燕,谷飞飞,刘莉. 免疫检查点抑制剂耐药机制及耐药后治疗策略的研究进展[J]. 实用肿瘤学杂志, 2017, 31(4): 353-358.
[12]	刘洋洋, 谷飞飞, 梁金燕综述, 刘莉审校. 髓源性抑制细胞在肺癌中的研究进展[J]. 实用肿瘤学杂志, 2016, 30(3): 257-261.
[13]	张锐, 王智煜, 文孝婷综述, 赵晖审校. 肿瘤免疫抑制微环境对肿瘤免疫治疗作用的研究进展[J]. 实用肿瘤学杂志, 2016, 30(2): 167-171.
[14]	黄娟娟, 王雯欣综述, 曹峰林审校. 血液系统恶性肿瘤细胞免疫治疗的研究进展[J]. 实用肿瘤学杂志, 2016, 30(1): 61-65.
[15]	全丽娜,刘爱春,郭秀臣,李莲乔,贾垂明. B非霍奇金淋巴瘤患者Th17、Treg水平及Th17/Treg失衡的研究[J]. 实用肿瘤学杂志, 2013, 27(5): 400-405.